Observational studyJournal of glaucoma2026
Ab Interno Minimally Invasive Glaucoma Surgery Effectiveness in Black Patients: An IRIS Registry Study.
Observational study in Journal of glaucoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Twelve-Month Outcomes of iStent Infinite in Severe Open-Angle Glaucoma Compared with iStent Inject W in Mild-to-Moderate Disease.Journal of clinical medicine · 2026Article
- Real-World Outcomes of Combined Goniotomy and Canaloplasty Using the Streamline Surgical System.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PRÉCIS: MIGS in combination with cataract surgery resulted in clinically significant reductions in IOP and IOP-lowering medications up to 24 months in Black patients. PURPOSE: Describe outcomes following ab interno Minimally Invasive Glaucoma Surgery (MIGS) procedures US FDA cleared or approved for intraocular pressure (IOP) reduction in primary open angle glaucoma combined with cataract surgery and cataract surgery alone in Black patients.
methodsAn observational, retrospective study of glaucoma in Black patients treated with MIGS (Hydrus®, iStent Inject®, OMNI® Surgical System) with cataract surgery or cataract surgery alone, in the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). Deidentified data included glaucoma diagnosis, procedure data, IOP, and medication use from preoperatively through 24 months. The study period was 07/01/2016 and 12/31/2023. Eligible patients identified via Current Procedural Terminology codes coupled with electronic health records. Outcomes were changes in IOP, and medication class usage (months 6, 12, 18, and 24) stratified by baseline IOP (≤18; >18 mm Hg).
resultsIn 12,828 eyes of 12,828 patients, including 189 Hydrus, 491 iStent, 91 OMNI, and 12,057 cataract surgeries, mean IOP and medication use decreased significantly in each cohort. Mean IOP reductions were in the range of 1.2-2.7 mm Hg, and medication reductions were 0.4-1.0 medications across all cohorts and time points. In MIGS cohorts, IOP reductions were greater with higher baseline IOP, and medication reductions were greater with lower baseline IOP.
conclusionsEach MIGS procedure produced clinically and statistically significant reductions in both IOP and IOP-lowering medications up to 2 years postoperatively in Black patients. Surgeons could consider offering MIGS at the time of cataract surgery to this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.